Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VICL

Vical (VICL) Stock Price, News & Analysis

Vical logo

About Vical Stock (NASDAQ:VICL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.68
$3.15
52-Week Range
N/A
Volume
35,024 shs
Average Volume
1.44 million shs
Market Capitalization
$21.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Receive VICL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vical and its competitors with MarketBeat's FREE daily newsletter.

VICL Stock News Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Headlines

VICL Stock Analysis - Frequently Asked Questions

Vical Incorporated (NASDAQ:VICL) released its quarterly earnings data on Tuesday, February, 19th. The biotechnology company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). The biotechnology company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.04 million. Vical had a negative trailing twelve-month return on equity of 29.46% and a negative net margin of 1,002.10%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vical investors own include Caladrius Biosciences (CLBS), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC) and Idera Pharmaceuticals (IDRA).

Company Calendar

Last Earnings
2/19/2019
Today
5/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VICL
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,250,000.00
Net Margins
-1,002.10%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.62 million
Price / Cash Flow
N/A
Book Value
$1.82 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$21.01 million
Optionable
Not Optionable
Beta
0.32
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:VICL) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners